Sabena Sultan
Technik-/Wissenschafts-/F&E-Leiter bei Cell Therapy Ltd.
Profil
Sabena Sultan is currently the Director & Global Head-Research at Cell Therapy Ltd.
Prior to this, he worked as a Principal Investigator at University College London and King's College London.
He holds a doctorate degree from Imperial College London.
Aktive Positionen von Sabena Sultan
| Unternehmen | Position | Beginn |
|---|---|---|
Cell Therapy Ltd.
 Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Sabena Sultan
| Unternehmen | Position | Ende |
|---|---|---|
| University College London | Corporate Officer/Principal | - |
| King's College London | Corporate Officer/Principal | - |
Ausbildung von Sabena Sultan
| Imperial College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
